Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Perm J. 2015 Summer;19(3):21-7. doi: 10.7812/TPP/15-046. Epub 2015 Jun 1.

"Getting off the Bus Closer to Your Destination": Patients' Views about Pharmacogenetic Testing.

Author information

1
Research Scientist in Bioethics and Humanities at the University of Washington in Seattle. sbtrini@uw.edu.
2
Doctoral Candidate in the Institute for Public Health Genetics at the University of Washington in Seattle. tarabethanne@gmail.com.
3
Associate Professor in Bioethics and Humanities at the University of Washington in Seattle. smfllrtn@uw.edu.
4
Associate Investigator at the Group Health Research Institute in Seattle, WA. ralston.j@ghc.org.
5
Professor and Head of the Division of Medical Genetics at the University of Washington in Seattle. pair@uw.edu.
6
Executive Director and Senior Investigator at the Group Health Research Institute in Seattle, WA. larson.e@ghc.org.

Abstract

The authors conducted focus groups with patients prescribed antidepressants (pilot session plus 2 focus groups, n = 27); patients prescribed carbamazepine (2 focus groups, n = 17); and healthy patients (2 focus groups, n = 17). Although participants understood the potential advantages of pharmacogenetic testing, many felt that the risks (discrimination, stigmatization, physician overreliance on genomic results, and denial of certain medications) may outweigh the benefits. These concerns were shared across groups but were more strongly expressed among participants with chronic mental health diagnoses.

PMID:
26057686
PMCID:
PMC4500477
DOI:
10.7812/TPP/15-046
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center